Primer: Eikon Therapeutics (EIKN US) - Aug 2026
Eikon Therapeutics is a clinical-stage biopharmaceutical company leveraging a proprietary, high-throughput drug discovery platform that...
98 Views
Eikon Therapeutics (EIKN US): Synthetic Expert Call Transcript (04 Aug 2026)
Platform-to-Pipeline Divergence: Eikon Therapeutics has shifted from an AI-and-imaging hardware platform provider to a late-stage clinical...
121 Views
Eikon Therapeutics (EIKN): Six Months Later: Priced for Perfection, Punished by Reality
​Eikon's aggressive pricing led to a nearly 50% stock decline in six months, making it one of 2026's weakest biotech IPO performers despite solid...
159 Views
Curator's Cut: Going Private, Getting Active & Reviewing Public Market Premieres
​Discover the latest standout themes in private markets, activist situations in Japan, and global IPO pipelines in this Curator's Cut. Share your...
333 Views
Eikon Therapeutics (EIKN): Late-Stage Immuno-Oncology IPO Prices with Strength, Flops on Debut
​Eikon Therapeutics' IPO disappoints with weak aftermarket performance, revealing a disconnect between bookbuilding strength and true buy-side...
331 Views